Study S000064

Effect of Dulaglutide vs Empagliflozin on Non-alcoholic Fatty Liver Disease of Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05946148
Acronym: NAMELS-18
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 78
Start: 2018-06-01
Primary completion: 2021-05-31
Lead sponsor: National and Kapodistrian University of Athens
Conditions: Non-Alcoholic Fatty Liver Disease; Liver Steatosis
Interventions: DRUG:Empagliflozin; DRUG:Dulaglutide; DRUG:Control Rx
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Liver Fat Fraction reduction [52 weeks]
>30% Liver Fat Fraction reduction [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.